Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgery

Trial Profile

Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgery

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 Planned number of patients changed from 20 to 30.
    • 30 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top